fda approval in melanoma, priority reviews in aml and wm, ndas in melanoma and sclc, and more
Published 6 years ago • 140 plays • Length 9:18
Download video MP4
Download video MP3
Similar videos
-
9:25
fda approvals in large b-cell lymphoma and melanoma, priority reviews in cscc and nsclc, and more
-
10:29
fda approval in melanoma, priority review in dlbcl, rcc, and ntrk fusion–positive tumors
-
10:49
fda approvals in melanoma and breast cancer, and priority reviews in prostate cancer and more
-
8:48
fda approval in aml, priority review designation in nsclc, and more
-
9:37
fda approvals in nhl and cinv, priority reviews in melanoma and breast cancer, and more
-
5:21
fda approvals in cll and all, nda accepted in melanoma, and more
-
8:45
fda approvals in gvhd, crc, and aml, a priority review in mcl, and more
-
10:46
fda approval in all, priority reviews in cml and breast cancer, and more
-
12:40
fda approval in aml, priority review in prostate cancer, ema chmp recommendations, and more
-
7:57
fda approvals in breast cancer and melanoma, disappointing results in hnscc, and more
-
8:51
fda approvals in prostate cancer and nsclc, priority review in aml, odac in all, and more
-
7:28
fda approvals in pml, nsclc, and breast cancer, priority review in dlbcl, and more
-
0:31
preview: fda approvals in cll and all, nda accepted in melanoma, and more
-
7:11
review on 2016 fda approvals, halt on aml trials, and more
-
1:49
dr. luke on the fda approval of adjuvant nivolumab in melanoma
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
9:29
fda approvals in all and breast cancer, priority reviews in cml and follicular lymphoma, and more
-
8:00
fda approval in rcc, european approvals in myeloma and melanoma, and 2016 aua highlights
-
10:00
fda approval in breast cancer, review period extended in aml, 2019 aacr highlights, and more
Clip.africa.com - Privacy-policy